Repligen Corporation Repligen Corporation

Repligen Corporation

RGEN

Rangering i aksjer #1908
Repligen Corporation specializes in the creation and distribution of advanced... Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
Aksjekurs
$175.15
Markedsverdi
$11.12B
Endring (1 dag)
-0.15%
Endring (1 år)
14.78%
Land
US
Handel Repligen Corporation (RGEN)

Kategori

Healthcare
Driftsmargin for Repligen Corporation (RGEN)
Driftsmargin per October 2026 TTM: 8.32%
Ifølge Repligen Corporation sine siste økonomiske rapporter og aksjekurs er selskapets nåværende driftsmargin (TTM) 8.32%. Ved slutten av 2023 hadde selskapet en driftsmargin på 7.54%.
Historikk for driftsmargin for Repligen Corporation fra 2000 til 2026
Driftsmargin ved slutten av hvert år
År Driftsmargin Endre
2026 (TTM) 8.32% -250.45%
2024 -5.53% -173.34%
2023 7.54% -54.77%
2022 16.67% -16.27%
2021 19.91% 71.34%
2020 11.62% 110.89%
2019 5.51% -58.85%
2018 13.39% 34.98%
2017 9.92% -35.08%
2016 15.28% -7.28%
2015 16.48% -2.02%
2014 16.82% -49.87%
2013 33.55% 88.48%
2012 17.80% -1,399.27%
2011 -1.37% -95.02%
2010 -27.50% -308.18%
2009 13.21% -92.90%
2008 186.00% -1,534.08%
2007 -12.97% 37.25%
2006 -9.45% -78.74%
2005 -44.46% -69.08%
2004 -143.77% 119.33%
2003 -65.55% -49.45%
2002 -129.67% -58.50%
2001 -312.46% 177.15%
2000 -112.74% 0.00%
Driftsmargin for lignende selskaper eller konkurrenter
Selskap Driftsmargin Forskjell i driftsmargin Land
31.28% -96.24%
US
12.36% -98.51%
FR
0.00% -
JP
9.83% -98.82%
US
0.00% -
CH
Hva er selskapets Driftsmargin?
Driftsmargin er en nøkkelindikator for å vurdere lønnsomheten til et selskap. Høyere Driftsmargins er vanligvis bedre, da de viser at selskapet kan selge sine produkter eller tjenester for mye mer enn produksjonskostnadene. Driftsmargin beregnes ved å dele selskapets inntjening med inntektene.